LIVN
LivaNova PLC
LIVN's fundamentals are mixed: it returned to profit, but its operating margin fell 4 points to 11%. At 30x earnings, it's trading less than half its usual 113x. Analysts expect earnings growth.
LIVN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
LIVN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LIVN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $90.20 | — |
| Cheap | 29x | $87.18 | -3.3% |
| Current | 30x | $90.20 | — |
| Fair | 112x | $337 | +274% |
| Expensive | 769x | $2,314 | +2465% |
Historical ranges are pointers, not guarantees.
LIVN's PE is in its cheap range at 30x. If earnings grow as analysts expect, today's price would be 20x next year's earnings.
LIVN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for LIVN, with profitability holding steady.
LIVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.53 | +50% |
| Q3 2026 | $3.01 | +$6.99 |
| Q2 2026 | $3.39 | +$7.26 |
| Q1 2026 | $1.96 | +$6.03 |
| Q4 2025 | -$4.45 | -484% |
| Q3 2025 | -$3.98 | -1048% |
| Q2 2025 | -$3.87 | -$3.55 |
| Q1 2025 | -$4.07 | -$3.47 |
| Q4 2024 | $1.16 | +262% |
LIVN has returned to profit: it earned $3.01 per share over the past year, after losing money the year before.
LIVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $393.1M | +9.9% |
| Q2 2026 | $390.6M | +11% |
| Q1 2026 | $362.3M | +14% |
| Q4 2025 | $360.9M | +12% |
| Q3 2025 | $357.8M | +12% |
| Q2 2025 | $352.5M | +11% |
| Q1 2025 | $316.9M | +7.4% |
| Q4 2024 | $321.8M | +3.8% |
LIVN's revenue has grown year over year for 16 quarters in a row: $393M last quarter, up 9.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.2% | -7.9 points |
| Q2 2026 | 13% | -2.7 points |
| Q1 2026 | 11% | -3.9 points |
| Q4 2025 | 12% | +0.3 points |
| Q3 2025 | 15% | +3.9 points |
| Q2 2025 | 15% | +2.8 points |
| Q1 2025 | 15% | +9.8 points |
| Q4 2024 | 12% | +40 points |
LIVN's operating margin was 7.2% last quarter, down 7.9 points from the same quarter a year ago.
LIVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $42.9M | -31% |
| Q2 2026 | $35M | -27% |
| Q1 2026 | $926K | -93% |
| Q4 2025 | $50.2M | -27% |
| Q3 2025 | $62.2M | +89% |
| Q2 2025 | $47.8M | +53% |
| Q1 2025 | $13.2M | +268% |
| Q4 2024 | $68.3M | +66% |
LIVN still generates free cash flow, though less than at its 2024 peak: $129M over the past year.
LIVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +1.1M shares |
| 1 year | +4% | +2.2M shares |
| 3 years | +6.3% | +3.4M shares |
| 5 years | +11% | +5.8M shares |
| Available history | +19% | +9M shares |
LIVN has 57M diluted shares, up 4% from a year ago.
LIVN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -0.6x | Net Cash |
| Q4 2024 | 1.3x | Healthy |
LIVN has more cash than debt.
LIVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.0 | Neutral |
| Stochastic | 56.1 | Neutral |
LIVN's weekly RSI is 67 (neutral) and its Stochastic is 56 (neutral).
LIVN PE vs Healthcare Sector
| Metric | LIVN | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 26x | 16% above |
| PE % | 19 | 29 | 10 pts below |
LIVN is trading at 30x earnings, a 16% premium to the Healthcare sector's median of 26x.
LIVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.7 | 12% above |
| 20 week MA | $80.3 | 12% above |
| 50 week MA | $72.3 | 25% above |
| 100 week MA | $59.7 | 51% above |
| 200 week MA | $55.5 | 62% above |
LIVN is in an uptrend: it's above all five of its weekly moving averages, and 62% above its 200-week average.
LIVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $75.4 | $67.4 | -11% |
| 2021 | $67.4 | $85.2 | +26% |
| 2022 | $85.2 | $53.7 | -37% |
| 2023 | $53.7 | $51.7 | -3.6% |
| 2024 | $51.7 | $46.6 | -10% |
| 2025 | $46.6 | $62.9 | +35% |
| 2026 YTD | $62.9 | $90.2 | +43% |
LIVN is up 43% so far in 2026, after finishing lower in four of the previous six years.